Home / Deep Research / Hypermobile Ehlers-Danlos Syndrome

Hypermobile Ehlers-Danlos Syndrome

Question: You are an expert researcher providing comprehensive, well-cited information.

2026-06-13
Falcon MONDO:0007523 Model: Edison Scientific Literature 39 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Prepare a focused, citation-rich deep research report for a dismech Disease entry called 'Hypermobile Ehlers-Danlos Syndrome'. Research objectives: define disease boundary and synonyms including hEDS and EDS hypermobility type; clarify that the molecular basis remains unresolved and diagnosis is clinical; distinguish hEDS from hypermobility spectrum disorders and nonsyndromic generalized joint hypermobility; summarize shared connective-tissue/ECM, pain, proprioceptive, autonomic, gastrointestinal, mast-cell/inflammatory, and psychosocial comorbidity evidence without overstating causality; identify core phenotypes including generalized joint hypermobility, joint instability/subluxation/dislocation, chronic pain, soft or hyperextensible skin, easy bruising, fatigue, dysautonomia/POTS, GI symptoms, and mitral valve/aortic root findings where supported; summarize treatment evidence including physical therapy, exercise/strengthening, pain management, and multidisciplinary care; identify MONDO, HPO, GO, and MAXO terms suitable for dismech YAML; include GeneReviews, 2017 classification/nosology, recent 2023-2024 reviews, and primary studies with PMID identifiers; flag evidence limitations, diagnostic circularity, and lack of validated genetic biomarkers. Do not invent citations; provide exact PMID identifiers for key claims and prefer PubMed-indexed sources.

Hypermobile Ehlers–Danlos Syndrome (hEDS): focused deep research report (for dismech Disease entry)

0) Executive summary

Hypermobile Ehlers–Danlos syndrome (hEDS) is the most common EDS subtype and is defined by a clinical diagnostic framework emphasizing generalized joint hypermobility plus systemic/musculoskeletal features and explicit exclusion of alternative diagnoses; no validated genetic or molecular biomarker is currently available for routine diagnosis, and the molecular basis remains unresolved. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)

A key boundary in contemporary practice is the 2017-era separation of hEDS from hypermobility spectrum disorders (HSD)—the latter covering symptomatic hypermobility presentations that do not meet full hEDS criteria—while nonsyndromic generalized joint hypermobility (GJH) denotes joint laxity without the systemic/persistent symptomatic pattern expected in hEDS/HSD. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 27-30)

Across recent cohorts and reviews, core phenotypes include generalized joint hypermobility with instability/subluxations/dislocations, chronic pain, fatigue, common gastrointestinal symptoms (often functional gut–brain disorders), autonomic complaints including orthostatic intolerance/POTS, and frequent psychosocial comorbidity (anxiety/depression). Associations with mast-cell activation and inflammatory mechanisms are widely discussed but remain unproven as causal; recent GI-focused guidance explicitly states mechanistic links to autonomic dysfunction or mast-cell activation are unclear despite clinical co-occurrence. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2, song2023psychologicalinterventionsfor pages 1-2)

Management is symptom-focused and typically multidisciplinary, centered on patient education, physical therapy/exercise/proprioception and joint stabilization strategies, and multimodal pain care; evidence quality is limited, with persistent gaps in high-quality clinical practice guidelines and randomized trials in several domains (including surgery). (peterson2018physicalandmechanical pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

1) Key concepts, definitions, synonyms, and disease boundary

1.1 Preferred term and synonyms

Recent genetics and clinical reviews describe hypermobile Ehlers–Danlos syndrome as the entity historically referred to as EDS hypermobility type or type III EDS, and overlapping older terminology includes joint hypermobility syndrome (JHS) in some literature. Because outdated nosology contributes to cohort misclassification and irreproducible genetic findings, current work emphasizes contemporary terminology and criteria for research and clinical clarity. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)

1.2 Clinical diagnosis and unresolved molecular basis

Multiple sources emphasize that hEDS is unusual among EDS subtypes in lacking a confirmed monogenic cause and therefore remains a clinical diagnosis. A 2022 critical appraisal of genetic studies states that diagnosis of hEDS “relies solely on a clinical diagnosis since its molecular aetiology remains unknown,” and highlights that the genetics literature is “scant, dispersed and conflicting” partly due to historical terminology and cohort heterogeneity. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

A 2024 clinic cohort likewise states that gene variants unique to hEDS/HSD are unknown (while noting emerging, not-yet-established candidates), reinforcing that the clinical framework remains central. (darakjian2024similaritiesanddifferences pages 1-3)

1.3 2017-era adult diagnostic framework (summary)

Later summaries of the 2017 adult hEDS framework describe three concurrent criteria: - Criterion 1: generalized joint hypermobility (often operationalized by Beighton thresholds that vary by age). (ganesh2024longcovidand pages 2-3) - Criterion 2: additional systemic and/or musculoskeletal features (often structured as “Feature A/B/C” sets, including systemic connective tissue manifestations, family history, and musculoskeletal complications such as chronic pain and recurrent atraumatic dislocations/instability). (forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3) - Criterion 3: exclusion of alternative diagnoses and attention to findings inconsistent with hEDS (e.g., “unusual skin fragility” and exclusion of other heritable/acquired connective-tissue disorders, including autoimmune rheumatologic conditions when relevant). (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8)

An important implementation point is that genetic testing is not confirmatory for hEDS, but can be valuable in Criterion 3 (excluding other syndromic/monogenic disorders). (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

1.4 Boundary distinctions: hEDS vs HSD vs nonsyndromic GJH

  • hEDS vs HSD: The 2017 diagnostic framework separated hEDS from hypermobility spectrum disorders (HSD). In a Mayo Clinic intake cohort (2019–2024) applying 2017 criteria, 66.5% were diagnosed with HSD (n=1389) and 20.3% with hEDS (n=423), illustrating that many symptomatic hypermobility presentations fall outside the more specific hEDS criteria. (darakjian2024similaritiesanddifferences pages 1-3)
  • hEDS/HSD vs nonsyndromic GJH: Reviews of the hypermobility spectrum emphasize that generalized joint hypermobility can occur without the systemic/persistent symptomatic features expected in hEDS/HSD, supporting a conceptual continuum from asymptomatic/nonsyndromic hypermobility to symptomatic HSD to hEDS when full criteria are met. (scicluna2023thegeneticsof pages 27-30)

1.5 Diagnostic circularity and limitations

Because hEDS is defined by a symptom-based framework with nonspecific features, studies of “comorbidities” can become circular if they examine outcomes that overlap with diagnostic criteria (e.g., pain, instability, some systemic features). Large clinic datasets show extensive symptom overlap between hEDS and HSD, underscoring the imperfect boundary and the importance of careful phenotyping and exclusionary evaluation. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

Supporting the importance of exclusionary workups, a 2025 clinical cohort study reported that among 178 patients meeting 2017 hEDS criteria, genetic testing identified an alternative or additional diagnosis in 26.4%, emphasizing that “hypermobility” is a shared phenotype across multiple disorders and that Criterion 3 is clinically consequential. (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2) Current understanding of pathophysiology and mechanistic hypotheses (cautious synthesis)

2.1 Connective tissue/ECM framing

hEDS is classically framed as a heritable connective tissue disorder, with the broader EDS concept centered on joint hypermobility, skin hyperextensibility, and tissue fragility. However, unlike other EDS types, the molecular basis of hEDS remains unknown, and mechanistic accounts (e.g., ECM remodeling, cell–matrix interactions, inflammatory/pain signaling) remain hypotheses requiring further validation. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2.2 Pain and proprioception

Recent clinical summaries emphasize chronic pain and proprioceptive impairment as common and disabling. Pediatric/rehabilitation-oriented evidence describes decreased joint position sense and motion incoordination in hypermobility disorders; however, controlled trial evidence for specific therapies remains limited. (ganesh2024longcovidand pages 3-4, peterson2018physicalandmechanical pages 1-2)

2.3 Autonomic dysfunction / POTS

Autonomic symptoms and POTS are commonly reported alongside hEDS/HSD. A GI-focused clinical review states that autonomic dysfunction (including POTS) has been documented in around 30% of hypermobility-disorder patients and may exacerbate GI symptoms, but mechanistic links remain unclear. (lam2023gastrointestinalsymptomsand pages 1-2)

The same review describes bidirectional clinical co-occurrence estimates: POTS in up to 40% of hypermobility disorders and hypermobility disorders in ~25% of POTS cohorts. (lam2023gastrointestinalsymptomsand pages 3-4)

2.4 Gastrointestinal symptoms

A 2023 Frontline Gastroenterology review describes a high GI symptom burden in hypermobility disorders (hEDS/HSD), with prevalence reported between 30% and 96%, and emphasizes that symptoms are often attributable to disorders of gut–brain interaction rather than proven structural dysmotility; the true prevalence of dysmotility remains unknown due to referral bias, retrospective designs, and confounding medications (notably opioids). (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

Specific estimates in that review include functional dyspepsia “up to 50%” in secondary-care hypermobility-disorder patients and slow colonic transit in 10–20% (with caveats about heterogeneous testing and populations). (lam2023gastrointestinalsymptomsand pages 3-4)

2.5 Mast-cell/inflammatory associations (avoid overstatement)

Mast cell activation syndrome (MCAS) is frequently discussed in hypermobility communities and appears in multidisciplinary clinical conversations. However, the 2023 GI review explicitly states that the role of mast cell activation in GI symptoms is not known despite associations with POTS and suggested links to MCAS; it also warns that some proposed biomarkers (e.g., diamine oxidase) are not reliable and that diagnostic guidelines are often not followed. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)

A genetics/diagnosis-focused review also notes that conditions such as hereditary alpha-tryptasemia can produce symptoms resembling hEDS and recommends baseline tryptase assessment as part of differential diagnosis in appropriate cases, illustrating again that “mast-cell/inflammatory” signals can reflect overlapping diagnoses rather than a proven hEDS mechanism. (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2.6 Psychosocial comorbidity and illness uncertainty

Psychiatric comorbidity is common in hEDS/HSD and should be interpreted as co-occurring morbidity rather than an explanatory replacement for somatic disease. A 2023 scoping review reports that in one cohort of 106 hypermobile EDS patients, 42.5% had a psychiatric disorder; anxiety and depression were 23.6% and 25.5%, and pain symptoms were associated with nearly 10× increased odds of psychiatric disorder. (song2023psychologicalinterventionsfor pages 1-2)

A 2023 narrative review highlights illness uncertainty in hEDS, attributing it to multisystem complexity, unclear etiology, prolonged diagnostic trajectories, misdiagnosis, and perceived dismissal; it argues for clearer explanations and multidisciplinary best-practice care. (bulbenacabre2017anxiety&joint pages 102-108)

3) Core phenotypes and comorbidities (with recent statistics)

The following phenotype clusters are repeatedly supported across recent cohorts and reviews, with variable evidence strength and likely selection bias toward specialty clinics:

4) Treatment and management: current applications and real-world implementation

4.1 Physical therapy, exercise, and proprioceptive/joint-stabilization approaches

Across recent reviews, PT/OT-based strengthening, motor control training, and proprioceptive interventions are central to management. A 2018 pediatric systematic review found only two RCTs (n=86) for lower-limb PT interventions, with no clear benefit of the evaluated approaches and no sham/no-treatment controls; thus, overall effectiveness remains uncertain in that pediatric evidence base. (peterson2018physicalandmechanical pages 1-2)

More recent clinical summaries nonetheless recommend specialized PT/OT focusing on strengthening periarticular muscles and avoiding hyperextension, and they note hydrotherapy as an adjunct; such recommendations are consistent with real-world multidisciplinary clinic practices even when high-quality RCT evidence is limited. (ganesh2024longcovidand pages 3-4)

4.2 Dysautonomia/POTS symptom management

In hypermobility-related GI care, first-line POTS strategies include salt and water loading, exercise, compression, and withdrawal of aggravating medications, while recognizing that many POTS medications can have GI side effects. (lam2023gastrointestinalsymptomsand pages 3-4)

4.3 GI symptom management

The 2023 Frontline Gastroenterology review strongly emphasizes a biopsychosocial, harm-minimizing strategy: avoid overuse of gastric emptying tests; prioritize management of disorders of gut–brain interaction; address restrictive diets and nutritional compromise; and reserve clinically assisted nutrition/hydration for objectively demonstrated malnutrition or severe dysmotility syndromes. (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

4.4 Pain management and multidisciplinary care

Pain management is typically multimodal and multidisciplinary. A 2024 review of hypermobility/HSD management emphasizes symptom-focused pharmacology and non-pharmacologic therapies (PT/OT, hydrotherapy, pacing and activity modification), and explicitly advises avoiding opioids (noting potential worsening of outcomes and GI burden). (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)

4.5 Psychological interventions

A 2023 scoping review of psychological interventions in EDS/HSD identified only 10 studies (cohort/case studies) covering CBT, DBT, ACT, psychoeducation, and intensive interdisciplinary pain treatment, with most studies small (n<50) and poorly described; it concludes that psychological interventions are understudied and higher-quality trials are needed. (song2023psychologicalinterventionsfor pages 1-2)

A narrative review highlights the clinical importance of addressing illness uncertainty and the harms of dismissal/misattribution, supporting integration of psychological care within multidisciplinary models. (bulbenacabre2017anxiety&joint pages 102-108)

4.6 Surgery: evidence limitations and complication risk

Orthopaedic surgery in EDS/hEDS is challenging and evidence is limited. A 2024 scoping review found only Level III/IV evidence (retrospective cohorts, case series), no randomized clinical trials, and inconsistent outcomes; it reports significant complication burdens (including one retrospective review citing a 91% complication rate and infection rates >18× the institutional baseline), supporting conservative-first approaches and careful selection and counseling when surgery is considered. (schubart2024outcomesoforthopaedic pages 1-2)

4.7 Pregnancy/childbearing guidance

A 2024 scoping review plus expert co-creation project produced evidence-based clinical guidance for pregnancy/birth/postpartum care in hEDS/HSD, emphasizing individualized multidisciplinary planning and acknowledging limited high-quality evidence. The synthesis incorporated 14 primary research studies and 21 case studies totaling 1,260,317 participants. (pezaro2024managementofchildbearing pages 1-2)

A large international survey (N=947; 1338 pregnancies) reported higher-than-typical incidences of several obstetric complications (e.g., pre-eclampsia, preterm birth, postpartum hemorrhage, hyperemesis gravidarum, PTSD), but inference is limited by self-selected survey design. (lam2023gastrointestinalsymptomsand pages 2-3)

5) Recent developments and latest research (prioritizing 2023–2024)

Key 2023–2024 developments relevant to a dismech disease entry include:

1) Systematic/comparative phenotyping of hEDS vs HSD in large clinic cohorts, quantifying overlap and differences and reinforcing that both diagnoses carry high multisystem symptom burdens. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

2) GI-focused clinical management syntheses that explicitly address risk of iatrogenic harm, emphasize gut–brain disorders, and clearly state the uncertain mechanistic role of autonomic dysfunction and mast-cell activation despite frequent clinical co-occurrence. (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

3) Pregnancy/childbearing guideline co-creation that integrates limited evidence with multidisciplinary expert/patient input, illustrating how management is evolving via pragmatic consensus where RCT evidence is sparse. (pezaro2024managementofchildbearing pages 1-2)

4) Updated synthesis of limited evidence for psychological interventions in EDS/HSD, reinforcing that multidisciplinary programs integrating physiotherapy plus psychological strategies appear most promising but remain under-tested in larger RCTs. (song2023psychologicalinterventionsfor pages 1-2)

5) Surgery evidence mapping emphasizing lack of RCTs and high complication risks, useful for dismech “real-world implementation” sections that caution against overconfident claims. (schubart2024outcomesoforthopaedic pages 1-2)

6) Expert opinions and authoritative analysis (with caveats)

Across the retrieved literature, authoritative consensus themes include:

  • hEDS is clinical, not molecularly confirmed; genetic testing’s role is primarily differential diagnosis and exclusion of alternative disorders. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)
  • Symptom overlap between hEDS and HSD is substantial, and available evidence does not yet provide a definitive biomarker-based boundary; clinical criteria define categories that remain under active refinement. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
  • Mechanistic hypotheses (ECM remodeling, inflammatory signaling, autonomic dysfunction, mast-cell activation) should be framed as plausible contributors or associated conditions, not proven causes of the full syndrome. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, lam2023gastrointestinalsymptomsand pages 1-2)
  • Evidence quality gaps remain large: a guideline-focused review found absence of good-quality clinical practice guidelines for diagnosis/monitoring/treatment and identifies major unmet needs (prevalence, natural history, cardiac risk, medical/surgical interventions). (sulli2018ehlersdanlossyndromesstate pages 2-3)

7) Evidence limitations, risks of overinterpretation, and curation flags

1) No validated genetic biomarker for hEDS: genetics studies have been conflicting; cohort misclassification and outdated nosology contribute to irreproducibility. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

2) Diagnostic circularity: Because many diagnostic criteria are symptom-based (pain, instability, systemic features), downstream “comorbidity” research can inadvertently re-measure diagnostic components. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

3) Selection bias: Many prevalence estimates come from tertiary centers or self-reported clinic questionnaires and may not generalize; GI motility testing is not systematic and is confounded by medications, especially opioids. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)

4) Mechanistic uncertainty: Clinical associations with POTS and MCAS are common, but causal pathways are not established; guidelines caution against non-evidence-based testing and interventions. (lam2023gastrointestinalsymptomsand pages 1-2)

5) Guidelines and RCT gaps: Reviews document absence of high-quality clinical practice guidelines and limited RCT evidence across interventions, including surgery. (schubart2024outcomesoforthopaedic pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

6) Primary 2017 nosology + GeneReviews retrieval limitation: This tool session did not successfully retrieve the full-text primary 2017 EDS nosology paper or the official GeneReviews chapter with PubMed PMID. The entry should therefore include an explicit curation step to add these primary citations during final YAML production. (forghani2019updatesinclinical pages 2-3, scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

8) DisMech-ready structured content

The following artifacts can be directly used to scaffold a dismech YAML entry.

Table (click to expand)
Topic Summary Key quantitative / defining details Supporting citations
Preferred name and synonyms Hypermobile Ehlers-Danlos syndrome is the current preferred term. Common historical synonyms include EDS hypermobility type, type III EDS, and overlap terminology with joint hypermobility syndrome (JHS) in older literature. Current literature emphasizes the 2017 nosology and warns that older labels can blur cohorts and reduce reproducibility in research. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)
Disease boundary: what hEDS is hEDS is an EDS subtype defined by generalized joint hypermobility plus systemic/musculoskeletal features and exclusion of alternative diagnoses. It is not established by a molecular test. Core phenotype includes GJH, joint instability/subluxation/dislocation, chronic pain, milder skin involvement than some other EDS types, fatigue, autonomic and GI symptoms in many patients. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Molecular basis and diagnostic mode The molecular basis of hEDS remains unresolved; therefore diagnosis is clinical, not biomarker- or gene-confirmed in routine practice. Genetic testing is mainly used to identify or exclude other heritable connective-tissue disorders rather than to confirm hEDS itself. Reviews note that gene findings proposed for hEDS have been conflicting or non-reproducible, and hEDS currently lacks a validated monogenic biomarker. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)
Adult diagnostic framework: Criterion 1 Criterion 1 requires generalized joint hypermobility (GJH). Beighton thresholds summarized in recent reviews of the 2017 framework: ≥6 in pre-pubertal children/adolescents, ≥5 from puberty to age 50, ≥4 over age 50. Adult hEDS diagnosis uses the 2017 criteria after biological maturity. (ganesh2024longcovidand pages 3-4, ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
Adult diagnostic framework: Criterion 2 Criterion 2 requires at least two of three feature sets: Feature A systemic connective-tissue manifestations, Feature B positive family history, and Feature C musculoskeletal complications. This structure is repeatedly summarized in later reviews of the 2017 criteria. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3)
Criterion 2, Feature A examples Feature A captures systemic signs compatible with a heritable connective-tissue disorder. Examples listed in recent summaries include unusually soft/velvety skin, mild skin hyperextensibility, unexplained striae, recurrent abdominal hernias, atrophic scarring, dental crowding, pelvic organ prolapse, marfanoid habitus, mitral valve prolapse, and aortic root dilatation. (ganesh2024longcovidand pages 3-4, ganesh2024longcovidand pages 2-3)
Criterion 2, Feature B Feature B is positive family history. Usually defined as a first-degree relative independently meeting current hEDS criteria. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3)
Criterion 2, Feature C examples Feature C captures musculoskeletal complications typical of symptomatic hypermobility disorders. Examples include musculoskeletal pain in ≥2 limbs recurring daily for ≥3 months, chronic widespread/generalized pain for ≥3 months, recurrent atraumatic dislocations, or frank joint instability. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3)
Adult diagnostic framework: Criterion 3 Criterion 3 requires exclusion of alternative diagnoses and attention to findings inconsistent with hEDS. Key exclusions repeatedly noted include unusual skin fragility and exclusion of other heritable/acquired connective-tissue disorders, including autoimmune rheumatologic disease when relevant. (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
hEDS vs HSD Since 2017, patients with symptomatic hypermobility who do not fulfill full hEDS criteria are generally classified under hypermobility spectrum disorders (HSD) rather than hEDS. hEDS and HSD have substantial symptom overlap; in a Mayo cohort of 2088 clinic patients, 66.5% were diagnosed with HSD and 20.3% with hEDS using 2017 criteria. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
hEDS vs HSD: symptom overlap Both hEDS and HSD can present with high burdens of pain, subluxations, headaches, GI symptoms, mood symptoms, and autonomic complaints. In the 2024 Mayo cohort, common self-reported prevalences included joint pain 82.0% hEDS vs 88.9% HSD, subluxations 71.2% vs 72.6%, headache 68.1% vs 69.1%, anxiety 60.3% vs 69.3%, depression 52.2% vs 58.0%, nausea 54.6% vs 59.5%, constipation 53.0% vs 57.2%. (darakjian2024similaritiesanddifferences pages 1-3)
hEDS vs HSD: possible distinctions Available data suggest differences in distribution of manifestations, but boundaries remain imperfect and evidence is still evolving. hEDS patients may report more features suggestive of collagen/connective-tissue fragility such as dislocation, hernias, rectal prolapse, while some HSD cohorts report more joint/muscle, GI, sleep, allergy, neurologic, and psychological symptom burden. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
hEDS/HSD vs nonsyndromic generalized joint hypermobility Nonsyndromic generalized joint hypermobility (GJH) refers to joint laxity without the additional systemic or persistent symptomatic pattern needed for hEDS/HSD. Conceptually, the spectrum runs from asymptomatic GJH → symptomatic hypermobility/HSD → hEDS when full criteria are met. (scicluna2023thegeneticsof pages 27-30, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
Diagnostic limitations / circularity hEDS diagnosis remains challenging because the criteria are symptom-based, many manifestations are nonspecific, and features used to define the condition overlap with outcomes later studied as “comorbidities.” Recent registry work found alternative or additional diagnoses in 26.4% of patients who met 2017 hEDS criteria in one specialty cohort, underscoring the need for careful exclusionary evaluation. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

Table: This table summarizes the disease boundary, clinical diagnostic framework, and adjacent-condition distinctions for hypermobile Ehlers-Danlos syndrome. It is useful for building a precise dismech entry that separates hEDS from HSD and nonsyndromic generalized joint hypermobility while highlighting the lack of validated genetic biomarkers.

Table (click to expand)
Domain Phenotype / comorbidity Current understanding for hEDS/HSD disease entry Quantitative statistic(s) Evidence type Supporting citations
Musculoskeletal Generalized joint hypermobility (GJH) Core defining feature of hEDS; also common in HSD and therefore not disease-specific by itself. Often accompanied by impaired proprioception/motion coordination and recurrent injury. In a systematic review of EDS extracutaneous features, joint hypermobility was reported in 153/160 hypermobile EDS cases (95.6%). Systematic review; diagnostic review (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Musculoskeletal Joint instability, subluxations, dislocations Common and clinically central in both hEDS and HSD; recurrent atraumatic dislocations/instability are part of musculoskeletal diagnostic features. Mayo clinic cohort: subluxations self-reported in 71.2% of hEDS and 72.6% of HSD patients. Large cohort; diagnostic review (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Musculoskeletal / pain Chronic pain Very common, often chronic and disabling; pain should be considered a major clinical burden rather than a specific diagnostic biomarker. Systematic review of EDS complications: chronic pain in hypermobile EDS 139/157 (88.5%); joint pain across EDS cases 217/270 (80.4%). Mayo cohort: joint pain 82.0% in hEDS and 88.9% in HSD. Systematic review; cohort; pain review (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 1-2)
Skin / connective tissue Soft/velvety skin, mild hyperextensibility Typical but usually milder than in classical EDS; included among systemic connective-tissue features in adult criteria summaries. No robust pooled prevalence identified in retrieved recent sources; repeatedly listed as Feature A systemic signs. Diagnostic review; clinical review (ganesh2024longcovidand pages 2-3, ganesh2024longcovidand pages 3-4)
Skin / connective tissue Easy bruising, striae, mild tissue fragility Frequently reported in hEDS descriptions, but less specific than major skin fragility seen in other EDS subtypes; unusual skin fragility argues against hEDS and should prompt alternative diagnosis review. Quantitative prevalence not reliably established in retrieved sources. Diagnostic review; genetics/diagnosis review (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8, ganesh2024longcovidand pages 2-3)
Skin / connective tissue Hernias, pelvic organ prolapse, related tissue signs Considered part of systemic connective-tissue manifestations and may help distinguish hEDS from HSD when present in aggregate. No pooled prevalence from retrieved high-level sources; hernias/rectal prolapse were reported more often in hEDS than HSD in a 2024 cohort. Cohort; diagnostic review (darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3)
Fatigue Chronic fatigue / exercise intolerance Common across hEDS/HSD, often interacting with pain, dysautonomia, sleep issues, and deconditioning; causality remains multifactorial and not fully resolved. Systematic review: chronic fatigue in hypermobile EDS 61/63 (96.8%). Tertiary-center cohort summarized in 2024 review: >40% reported fatigue. Systematic review; comparative review (darakjian2024similaritiesanddifferences pages 8-9, lam2023gastrointestinalsymptomsand pages 1-2)
Autonomic Dysautonomia / orthostatic intolerance / POTS Strong clinical association, but mechanism remains uncertain; may aggravate fatigue, presyncope, palpitations, nausea, and exercise intolerance. Review cited autonomic dysfunction in ~30% of hypermobility-disorder patients; GI review states POTS occurs in up to 40% of hypermobility disorders and hypermobility is present in ~25% of POTS cohorts. Review; GI management review (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)
Gastrointestinal Functional GI symptoms overall GI symptoms are common and often attributed to disorders of gut–brain interaction; true prevalence of structural dysmotility is unknown. GI symptom prevalence across hypermobility disorders reported as 30%–96%. GI review / management review (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
Gastrointestinal Functional dyspepsia, dysphagia, nausea, constipation, IBS-C Frequently reported in hEDS/HSD; dysphagia, nausea, bloating, constipation, and IBS-C are among the recurring symptom clusters. Functional dyspepsia occurs in up to 50% of secondary-care hypermobility patients; slow colonic transit reported in 10%–20%. Mayo cohort: nausea 54.6% in hEDS vs 59.5% in HSD; constipation 53.0% vs 57.2%. GI review; comparative cohort (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3)
Neurologic / cognitive Headache, migraine, brain fog Common extra-articular manifestations; likely multifactorial and overlapping with dysautonomia, pain, sleep disturbance, and mood symptoms. Mayo cohort: headache 68.1% in hEDS vs 69.1% in HSD; migraine 53.7% vs 52.5%; brain fog 70.0% vs 74.7%. Large cohort (darakjian2024similaritiesanddifferences pages 1-3)
Immune / allergy Allergy / atopy Frequently self-reported in both hEDS and HSD, but not specific and not yet tied to a validated unifying mechanism. Mayo cohort: allergy reported in 77.0% of hEDS and 77.0% of HSD patients. Large cohort (darakjian2024similaritiesanddifferences pages 1-3)
Mast-cell / inflammatory Mast-cell activation associations MCAS/mast-cell involvement is commonly discussed clinically, but current evidence does not establish it as a proven causal mechanism for hEDS/HSD or associated GI/autonomic symptoms. Tertiary-center cohort summarized in 2024 comparative review reported >40% with mast-cell activation symptoms/comorbidity, but GI review explicitly states mechanistic links are unclear/unproven. Review; comparative review (darakjian2024similaritiesanddifferences pages 8-9, lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)
Psychosocial Anxiety, depression, psychiatric comorbidity Psychosocial comorbidity is common and should not be used to dismiss somatic disease burden; pain and diagnostic ambiguity may worsen distress. In one cohort of 106 hypermobile EDS patients, 42.5% had a psychiatric disorder; anxiety 23.6%, depression 25.5%. Mayo cohort: anxiety 60.3% in hEDS vs 69.3% in HSD; depression 52.2% vs 58.0%. Scoping review; cohort (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
Psychosocial Illness uncertainty Illness uncertainty is increasingly recognized because of delayed diagnosis, unclear etiology, multisystem symptoms, and prior dismissal/misattribution. No validated prevalence estimate identified in retrieved sources. Narrative review (bulbenacabre2017anxiety&joint pages 102-108)
Reproductive / pregnancy Pregnancy and childbearing considerations Pregnancy-related care should be individualized and multidisciplinary; attention is warranted for tissue fragility, pain, dysautonomia/POTS, GI issues, mental health, and postpartum recovery. International survey: 947 respondents, 1338 pregnancies; reported higher-than-general-population incidences of pre-eclampsia, preterm birth, postpartum hemorrhage, hyperemesis gravidarum, precipitate labor, PTSD, and other complications. Guideline scoping review synthesized 35 studies/case studies totaling 1,260,317 participants. Large survey; scoping review + expert guideline (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2)

Table: This table summarizes core clinical phenotypes and associated comorbidities relevant to a disease entry for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. It emphasizes what is common, what remains uncertain, and where quantitative estimates are available from recent reviews and cohorts.

Table (click to expand)
Management domain Practical approach for hEDS/HSD Evidence strength / limitations Supporting citations
Diagnosis / exclusion workup and role of genetic testing Diagnose hEDS clinically using 2017-style criteria: confirm generalized joint hypermobility, assess systemic and musculoskeletal features, and explicitly exclude other heritable/acquired connective-tissue disorders and unusual skin fragility. Genetic testing is mainly used to identify alternative diagnoses rather than confirm hEDS, because validated hEDS biomarkers/genes are lacking. Moderate support for exclusionary value of genetics, weak support for confirmation of hEDS itself. In one specialty cohort, 26.4% of patients meeting hEDS criteria had an alternative or additional diagnosis on genetic testing; however, no validated molecular biomarker confirms hEDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)
Education / activity modification Educate patients about joint protection, pacing, avoiding end-range hyperextension, recognizing instability triggers, and balancing activity against fatigue/post-exertional symptom flares. Tailor advice to symptom pattern and affected joints. Mostly expert review/consensus and observational evidence; few controlled trials. Helpful in practice but not strongly trial-validated. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72, sulli2018ehlersdanlossyndromesstate pages 2-3)
Physical therapy / strengthening / proprioception / orthoses-compression Refer to PT/OT focused on periarticular muscle strengthening, motor control, proprioception, and stability training; hydrotherapy may be useful. Closed-chain and low-impact exercise are often favored. Compression garments, insoles, and orthoses may help selected patients, especially for postural control or instability. Low-to-moderate evidence overall. Pediatric systematic review found only 2 RCTs (n=86) with no clear superiority of tested PT approaches and no sham/no-treatment controls; pilot studies suggest orthoses/compression can improve postural stability; some pregnancy-related reviews cite RCTs supporting proprioception/stabilization approaches. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, mcculloch2024investigatingtheacceptability pages 69-72, peterson2018physicalandmechanical pages 1-2)
Dysautonomia / POTS nonpharmacologic measures Use first-line conservative autonomic management when orthostatic intolerance/POTS is present: increased salt and water intake, compression, graded/modified exercise, withdrawal of aggravating medications, and symptom-adapted conditioning. In patients with post-exertional malaise, pacing and caution with exercise progression are advised. Mostly extrapolated from POTS care and review-level evidence; direct hEDS-specific trials are limited. Mechanistic links between dysautonomia and hEDS symptoms are plausible but not fully established. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2, ganesh2024longcovidand pages 3-4)
GI symptom management Use a biopsychosocial GI approach; prioritize disorders of gut-brain interaction before labeling structural dysmotility. Optimize oral diet/oral supplements first, limit unnecessary invasive testing, reduce iatrogenic harm, and manage symptom clusters (e.g., behavioral/dietary strategies, antiemetics/prokinetics, gut-brain neuromodulators, psychosocial support). Assisted feeding should generally be reserved for objective malnutrition or severe dysmotility syndromes. Moderate review support for management principles, but pathophysiology is uncertain and motility data are mostly retrospective/tertiary-center based. GI symptom prevalence is high (30%-96%), but true prevalence of structural dysmotility is unknown. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
Pain management / multidisciplinary pain care Prefer non-opioid multimodal pain care: PT/exercise, symptom-targeted pharmacology (e.g., some use of amitriptyline/NSAIDs), pacing, and multidisciplinary pain programs. Avoid chronic opioids where possible because they may worsen GI burden and outcomes. Evidence is limited and heterogeneous; much guidance is consensus- or review-based. Psychological and physical approaches appear more promising when integrated in multidisciplinary programs than when used in isolation. (lam2023gastrointestinalsymptomsand pages 3-4, pimiento2024ehlersdanlossyndromeand pages 7-10, ganesh2024longcovidand pages 3-4)
Psychological interventions Consider CBT/related therapies, psychoeducation, ACT/DBT-informed approaches, and interdisciplinary pain programs, especially when pain-related fear, anxiety, depression, self-management problems, or illness uncertainty are prominent. Low-quality evidence base. Scoping review identified only 10 mostly small cohort/case studies; later systematic review found 6 studies, with best results when psychological treatment was combined with physiotherapy/multidisciplinary care. More RCTs are needed. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
Surgery considerations / evidence quality / complication rates Reserve surgery for carefully selected indications after conservative care fails; counsel about tissue fragility, bleeding, delayed wound healing, infection risk, recurrent instability, and variable outcomes. Orthopedic procedures should be individualized and expectations tempered. Evidence is weak: 2024 scoping review found only Level III-IV studies, no RCTs, and inconsistent outcomes. One retrospective review cited a 91% complication rate and infection rate >18-fold institutional baseline; some smaller series report benefit in selected procedures, but recurrence/failure remains a concern. (schubart2024outcomesoforthopaedic pages 13-15, schubart2024outcomesoforthopaedic pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)
Pregnancy / childbearing management principles Use individualized multidisciplinary perinatal planning addressing tissue fragility, mobility/joint instability, pain, dysautonomia/POTS, GI symptoms, mast-cell disease history, wound healing, pelvic health, anesthesia considerations, and postpartum recovery. Moderate scoping-review/guideline support but limited high-quality primary evidence. Expert co-created guidance is available; a large international survey (947 respondents, 1338 pregnancies) reported higher-than-general-population rates of several complications, but survey design limits causal inference. (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2, pezaro2024managementofchildbearing pages 31-32)

Table: This table summarizes current management approaches for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders, with emphasis on where evidence is stronger, weaker, or mainly consensus-based. It is useful for translating the literature into a practical disease-entry management framework.

Table (click to expand)
Ontology Label Suggested ID (if known) Notes/usage in YAML Evidence support in retrieved sources
MONDO Hypermobile Ehlers-Danlos syndrome Primary disease term; verify exact MONDO ID in ontology browser before YAML release. Historical synonyms to capture in metadata: hEDS, EDS hypermobility type, type III EDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)
HPO Generalized joint hypermobility HP:0001382 Core phenotype; include as defining musculoskeletal feature. (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3)
HPO Joint dislocation HP:0001373 Use for recurrent dislocations; pair with subluxation/instability terms if available. (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
HPO Joint subluxation Common in hEDS/HSD; verify exact HPO term/ID in ontology browser. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, darakjian2024similaritiesanddifferences pages 1-3)
HPO Joint instability Useful if represented separately from dislocation/subluxation; verify in ontology browser. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3)
HPO Chronic pain HP:0012532 High-value phenotype for symptom burden; may coexist with more specific pain terms. (lam2023gastrointestinalsymptomsand pages 1-2, pimiento2024ehlersdanlossyndromeand pages 7-10)
HPO Fatigue HP:0012378 Common systemic symptom; consider chronic fatigue if a preferred child term is needed. (darakjian2024similaritiesanddifferences pages 8-9, scicluna2023thegeneticsof pages 34-38)
HPO Orthostatic intolerance HP:0004926 Broad autonomic phenotype; useful when POTS is unconfirmed. (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)
HPO Postural orthostatic tachycardia syndrome Candidate comorbidity term; verify exact HPO representation/ID in ontology browser. (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)
HPO Dysautonomia HP:0012330 Broad autonomic dysfunction term for multi-system entries. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, scicluna2023thegeneticsof pages 34-38)
HPO Functional gastrointestinal abnormality / disorder of gut-brain interaction Use a general GI symptom term if functional GI disorder term is unavailable; verify preferred HPO label. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
HPO Functional dyspepsia Candidate specific GI term; verify in ontology browser. (lam2023gastrointestinalsymptomsand pages 3-4)
HPO Constipation HP:0002019 Common GI symptom; useful alongside nausea/bloating if needed. (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 3-4)
HPO Nausea HP:0002018 Common GI/autonomic symptom. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 34-38)
HPO Dysphagia HP:0002015 Consider when upper GI/swallowing phenotype is prominent. (lam2023gastrointestinalsymptomsand pages 3-4)
HPO Anxiety HP:0000739 Frequent psychosocial comorbidity; avoid implying causation. (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
HPO Depression HP:0000716 Frequent psychosocial comorbidity; use with caution as associated feature. (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
HPO Easy bruising HP:0000978 Common tissue-fragility feature; not specific to hEDS. (ganesh2024longcovidand pages 2-3, scicluna2023thegeneticsof pages 27-30)
HPO Soft skin HP:0011359 Candidate systemic connective-tissue feature; verify if a more specific 'velvety skin' term is preferred. (ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Hyperextensible skin HP:0000974 Mild skin hyperextensibility is part of systemic feature set. (ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Abdominal hernia HP:0000023 Use for recurrent hernia/systemic tissue fragility burden. (darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Pelvic organ prolapse HP:0000139 Useful for systemic connective-tissue involvement. (ganesh2024longcovidand pages 2-3, pezaro2024managementofchildbearing pages 1-2)
HPO Headache HP:0002315 Common neurologic symptom. (darakjian2024similaritiesanddifferences pages 1-3)
HPO Migraine HP:0002076 Common specific headache phenotype. (darakjian2024similaritiesanddifferences pages 1-3)
HPO Cognitive impairment / brain fog 'Brain fog' may map better to a cognitive phenotype term; verify preferred HPO label/ID. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 34-38)
HPO Mitral valve prolapse HP:0001634 Include only as supported associated cardiovascular feature. (ganesh2024longcovidand pages 3-4)
HPO Aortic root dilatation HP:0002616 Include as associated feature where supported; usually mild in hEDS descriptions. (ganesh2024longcovidand pages 3-4)
GO Extracellular matrix organization GO:0030198 Candidate mechanistic GO process for connective-tissue/ECM hypotheses; mechanism remains unresolved in hEDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)
GO Cell-matrix adhesion GO:0007160 Candidate GO term for reported cell-matrix interaction abnormalities; verify fit for YAML scope. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)
GO Inflammatory response GO:0006954 Use cautiously; inflammatory signaling is hypothesized/associated, not established as causal. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, lam2023gastrointestinalsymptomsand pages 1-2)
GO Proprioception GO representation may not be ideal; verify whether a neurobiological process or phenotype ontology term is preferable. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72, peterson2018physicalandmechanical pages 1-2)
MAXO Physical therapy Core management term; verify exact MAXO ID in ontology browser. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, peterson2018physicalandmechanical pages 1-2)
MAXO Exercise therapy / therapeutic exercise Core management term for strengthening and conditioning; verify MAXO ID. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, kaabi2023…qualityof pages 28-32)
MAXO Muscle strengthening exercise Candidate more specific intervention term; verify MAXO label/ID. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72)
MAXO Proprioceptive training Candidate intervention term; verify in ontology browser. (pezaro2024managementofchildbearing pages 31-32, mcculloch2024investigatingtheacceptability pages 69-72)
MAXO Occupational therapy Useful adjunct management term for function/joint protection. (ganesh2024longcovidand pages 3-4)
MAXO Hydrotherapy Adjunct therapy mentioned in management reviews; verify term/ID. (ganesh2024longcovidand pages 3-4)
MAXO Orthotic device / orthoses For insoles, bracing, or supportive devices; verify preferred MAXO label. (mcculloch2024investigatingtheacceptability pages 69-72, schubart2024outcomesoforthopaedic pages 13-15)
MAXO Compression garment therapy For orthostatic intolerance/postural support; verify exact term/ID. (lam2023gastrointestinalsymptomsand pages 3-4, pezaro2024managementofchildbearing pages 31-32)
MAXO Pain management Broad intervention term; can group multimodal analgesic strategies. (pimiento2024ehlersdanlossyndromeand pages 7-10, pezaro2024managementofchildbearing pages 1-2, ganesh2024longcovidand pages 3-4)
MAXO Psychological therapy Broad parent term; use if specific CBT/ACT terms are not chosen. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
MAXO Cognitive behavioral therapy Best-supported named psychological approach in current reviews; verify ID. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
MAXO Multidisciplinary care Important care-model term; verify if represented directly in MAXO or encode via multiple interventions. (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

Table: This table lists candidate MONDO, HPO, GO, and MAXO terms for a dismech YAML entry on hypermobile Ehlers-Danlos syndrome. IDs are included only where reasonably confident from common ontology usage; blanks are intentionally left for ontology-browser verification rather than guessing.

9) Selected bibliography (URLs and publication dates as available in retrieved sources)

10) Required “PMID-first” note

Within the retrieved evidence package, several key sources are referenced by DOI and journal metadata, but PMID identifiers were not available in the tool outputs for these same sources. A final curation pass using PubMed (outside this tool session) is therefore required to attach exact PMIDs to the above DOIs and to add the missing primary 2017 nosology and GeneReviews references as requested.

References

  1. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2): Kirsty Scicluna, Melissa M. Formosa, Rosienne Farrugia, and Isabella Borg. Hypermobile ehlers–danlos syndrome: a review and a critical appraisal of published genetic research to date. Jul 2022. URL: https://doi.org/10.1111/cge.14026, doi:10.1111/cge.14026. This article has 27 citations and is from a peer-reviewed journal.

  2. (forghani2025hypermobileehlers–danlossyndrome pages 6-8): Irman Forghani, Julia See, and William C. McGonigle. Hypermobile ehlers–danlos syndrome: diagnostic challenges and the role of genetic testing. Genes, 16:530, Apr 2025. URL: https://doi.org/10.3390/genes16050530, doi:10.3390/genes16050530. This article has 6 citations.

  3. (darakjian2024similaritiesanddifferences pages 1-3): Ashley A Darakjian, Mira Bhutani, DeLisa Fairweather, S Christian Kocsis, Jessica J Fliess, Sami Khatib, Gabe J Weigel, Elizabeth J McCabe, Varsini Balamurugan, Evan E Perona, Jessica M Gehin, Emily R Whelan, Angita Jain, Hanna Sledge, David O Hodge, Todd D Rozen, Francis A Farraye, Ozan Soyer, Joseph Cheung, Stephanie L Grach, David Shirey Jr., Shilpa Gajarawala, Bala Munipalli, Chrisandra L Shufelt, Dacre R T Knight, and Katelyn A Bruno. Similarities and differences in self-reported symptoms and comorbidities between hypermobile ehlers–danlos syndrome and hypermobility spectrum disorders. Rheumatology Advances in Practice, Nov 2024. URL: https://doi.org/10.1093/rap/rkae134, doi:10.1093/rap/rkae134. This article has 17 citations and is from a peer-reviewed journal.

  4. (scicluna2023thegeneticsof pages 27-30): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, 2023.

  5. (lam2023gastrointestinalsymptomsand pages 3-4): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  6. (lam2023gastrointestinalsymptomsand pages 1-2): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  7. (song2023psychologicalinterventionsfor pages 1-2): Jessica Z. Song, Dorothy Luong, Estée C. H. Feldman, Susan Tran, Laure Perrier, Kathleen Eubanks, Mark Bayley, Monika Kastner, Maxwell Slepian, and Sarah E. P. Munce. Psychological interventions for individuals with ehlers-danlos syndrome and hypermobility spectrum disorder: a scoping review. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02799-y, doi:10.1186/s13023-023-02799-y. This article has 18 citations and is from a peer-reviewed journal.

  8. (peterson2018physicalandmechanical pages 1-2): Benjamin Peterson, Andrea Coda, Verity Pacey, and Fiona Hawke. Physical and mechanical therapies for lower limb symptoms in children with hypermobility spectrum disorder and hypermobile ehlers-danlos syndrome: a systematic review. Journal of Foot and Ankle Research, Nov 2018. URL: https://doi.org/10.1186/s13047-018-0302-1, doi:10.1186/s13047-018-0302-1. This article has 46 citations and is from a peer-reviewed journal.

  9. (sulli2018ehlersdanlossyndromesstate pages 2-3): Alberto Sulli, Rosaria Talarico, Carlo Alberto Scirè, Tadej Avcin, Marco Castori, Alessandro Ferraris, Charissa Frank, Jürgen Grunert, Sabrina Paolino, Stefano Bombardieri, Matthias Schneider, Vanessa Smith, Maurizio Cutolo, Marta Mosca, and Fransiska Malfait. Ehlers-danlos syndromes: state of the art on clinical practice guidelines. RMD Open, 4:e000790, Oct 2018. URL: https://doi.org/10.1136/rmdopen-2018-000790, doi:10.1136/rmdopen-2018-000790. This article has 46 citations and is from a peer-reviewed journal.

  10. (forghani2019updatesinclinical pages 2-3): Irman Forghani. Updates in clinical and genetics aspects of hypermobile ehlers danlos syndrome. Balkan Medical Journal, pages 12-16, Jan 2019. URL: https://doi.org/10.4274/balkanmedj.2018.1113, doi:10.4274/balkanmedj.2018.1113. This article has 59 citations.

  11. (ganesh2024longcovidand pages 2-3): Ravindra Ganesh and Bala Munipalli. Long covid and hypermobility spectrum disorders have shared pathophysiology. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1455498, doi:10.3389/fneur.2024.1455498. This article has 10 citations and is from a peer-reviewed journal.

  12. (ganesh2024longcovidand pages 3-4): Ravindra Ganesh and Bala Munipalli. Long covid and hypermobility spectrum disorders have shared pathophysiology. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1455498, doi:10.3389/fneur.2024.1455498. This article has 10 citations and is from a peer-reviewed journal.

  13. (darakjian2024similaritiesanddifferences pages 8-9): Ashley A Darakjian, Mira Bhutani, DeLisa Fairweather, S Christian Kocsis, Jessica J Fliess, Sami Khatib, Gabe J Weigel, Elizabeth J McCabe, Varsini Balamurugan, Evan E Perona, Jessica M Gehin, Emily R Whelan, Angita Jain, Hanna Sledge, David O Hodge, Todd D Rozen, Francis A Farraye, Ozan Soyer, Joseph Cheung, Stephanie L Grach, David Shirey Jr., Shilpa Gajarawala, Bala Munipalli, Chrisandra L Shufelt, Dacre R T Knight, and Katelyn A Bruno. Similarities and differences in self-reported symptoms and comorbidities between hypermobile ehlers–danlos syndrome and hypermobility spectrum disorders. Rheumatology Advances in Practice, Nov 2024. URL: https://doi.org/10.1093/rap/rkae134, doi:10.1093/rap/rkae134. This article has 17 citations and is from a peer-reviewed journal.

  14. (lam2023gastrointestinalsymptomsand pages 2-3): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  15. (bulbenacabre2017anxiety&joint pages 102-108): A Bulbena-Cabré. Anxiety & joint hypermobility: connecting mind and body. Unknown journal, 2017.

  16. (schubart2024outcomesoforthopaedic pages 1-2): Jane R. Schubart, Susan E. Mills, Scott A. Rodeo, and Clair A. Francomano. Outcomes of orthopaedic surgery in ehlers-danlos syndromes: a scoping review. BMC Musculoskeletal Disorders, Oct 2024. URL: https://doi.org/10.1186/s12891-024-07937-6, doi:10.1186/s12891-024-07937-6. This article has 9 citations and is from a peer-reviewed journal.

  17. (pezaro2024managementofchildbearing pages 1-2): Sally Pezaro, Isabelle Brock, Maggie Buckley, Sarahann Callaway, Serwet Demirdas, Alan Hakim, Cheryl Harris, Carole High Gross, Megan Karanfil, Isabelle Le Ray, Laura McGillis, Bonnie Nasar, Melissa Russo, Lorna Ryan, and Natalie Blagowidow. Management of childbearing with hypermobile ehlers-danlos syndrome and hypermobility spectrum disorders: a scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE, 19:e0302401, May 2024. URL: https://doi.org/10.1371/journal.pone.0302401, doi:10.1371/journal.pone.0302401. This article has 9 citations and is from a peer-reviewed journal.

  18. (hakim2024hypermobileehlersdanlossyndrome pages 1-2): A Hakim. Hypermobile ehlers-danlos syndrome. Unknown journal, 2024.

  19. (mcculloch2024investigatingtheacceptability pages 69-72): Sacha Clare McCulloch. Investigating the acceptability, suitability and feasibility of exercise for managing chronic orthostatic intolerance in ehlers-danlos syndrome. Text, Jan 2024. URL: https://doi.org/10.25949/26020618, doi:10.25949/26020618. This article has 0 citations and is from a peer-reviewed journal.

  20. (pezaro2024managementofchildbearing pages 31-32): Sally Pezaro, Isabelle Brock, Maggie Buckley, Sarahann Callaway, Serwet Demirdas, Alan Hakim, Cheryl Harris, Carole High Gross, Megan Karanfil, Isabelle Le Ray, Laura McGillis, Bonnie Nasar, Melissa Russo, Lorna Ryan, and Natalie Blagowidow. Management of childbearing with hypermobile ehlers-danlos syndrome and hypermobility spectrum disorders: a scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE, 19:e0302401, May 2024. URL: https://doi.org/10.1371/journal.pone.0302401, doi:10.1371/journal.pone.0302401. This article has 9 citations and is from a peer-reviewed journal.

  21. (pimiento2024ehlersdanlossyndromeand pages 7-10): DCN Pimiento and D Vergara-Garcia. Ehlers-danlos syndrome and fibromyalgia: beyond pain and fatigue: a systematic review. Unknown journal, 2024.

  22. (schubart2024outcomesoforthopaedic pages 13-15): Jane R. Schubart, Susan E. Mills, Scott A. Rodeo, and Clair A. Francomano. Outcomes of orthopaedic surgery in ehlers-danlos syndromes: a scoping review. BMC Musculoskeletal Disorders, Oct 2024. URL: https://doi.org/10.1186/s12891-024-07937-6, doi:10.1186/s12891-024-07937-6. This article has 9 citations and is from a peer-reviewed journal.

  23. (scicluna2023thegeneticsof pages 34-38): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, 2023.

  24. (kaabi2023…qualityof pages 28-32): N Al Kaabi. … quality of life, physical activity and symptom management in ehlers-danlos syndromes and generalized-hypermobility spectrum disorders: a mixed-methods …. Unknown journal, 2023.

Artifacts